0001415889-23-012142.txt : 20230811
0001415889-23-012142.hdr.sgml : 20230811
20230811163024
ACCESSION NUMBER: 0001415889-23-012142
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230810
FILED AS OF DATE: 20230811
DATE AS OF CHANGE: 20230811
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MILANO VINCENT
CENTRAL INDEX KEY: 0001187159
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31918
FILM NUMBER: 231164561
MAIL ADDRESS:
STREET 1: C/O VIROPHARMA INC
STREET 2: 405 EAGLEVIEW BLVD
CITY: EXTON
STATE: PA
ZIP: 19341
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aceragen, Inc.
CENTRAL INDEX KEY: 0000861838
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 043072298
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 EAGLEVIEW BOULEVARD
STREET 2: SUITE 212
CITY: EXTON
STATE: PA
ZIP: 19341
BUSINESS PHONE: 4843481600
MAIL ADDRESS:
STREET 1: 505 EAGLEVIEW BOULEVARD
STREET 2: SUITE 212
CITY: EXTON
STATE: PA
ZIP: 19341
FORMER COMPANY:
FORMER CONFORMED NAME: IDERA PHARMACEUTICALS, INC.
DATE OF NAME CHANGE: 20050912
FORMER COMPANY:
FORMER CONFORMED NAME: HYBRIDON INC
DATE OF NAME CHANGE: 19951211
4
1
form4-08112023_040818.xml
X0508
4
2023-08-10
0000861838
Aceragen, Inc.
ACGN
0001187159
MILANO VINCENT
C/O ACERAGEN, INC.
505 EAGLEVIEW BOULEVARD, SUITE 212
EXTON
PA
19341
true
false
false
false
0
Common Stock
2023-08-10
4
S
0
3283
0.5331
D
8987
D
The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.5513 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares reported on this Form 4 have been adjusted to reflect the Issuer's 1-for-17 reverse stock split of its common stock, effective January 17, 2023.
Of the reported securities beneficially owned, 544 shares are represented by unvested Restricted Stock Units.
/s/ Vincent J. Milano
2023-08-11